The QualityStocks Daily Friday, December 29th, 2023

Today's Top 3 Investment Newsletters

FreeRealTime(ROI) $0.4300 +205.40%

QualityStocks(CING) $3.9900 +101.52%

Schaeffer's(CYTK) $83.4400 +82.54%

The QualityStocks Daily Stock List

China SXT Pharmaceuticals (SXTC)

QualityStocks, StreetInsider, StockMarketWatch, TradersPro, The Online Investor and MarketClub Analysis reported earlier on China SXT Pharmaceuticals (SXTC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (FRA: 2RY0) is an innovative pharmaceutical firm that is engaged in researching, developing, manufacturing, marketing and selling traditional Chinese medicine which has been used by the Chinese for thousands of years.

The firm has its headquarters in Taizhou, the People’s Republic of China and was incorporated in 2005 by Feng Zhou. It operates as part of the health care industry, under the biotech and pharma sub-industry and serves consumers in China.

The company devotes its research and development efforts to the development of new products and serves drugstores, hospitals and commercial pharmaceutical firms in China. It provides its products under the Tong Ren Tang, Hui Chun Tang and Su Xuangtang brand names. The latter brand has over 2 centuries’ worth of history and is a very famous TCM brand as well as a symbol of culture and tradition in the country. Most of the company’s products are sold on a prescription basis.

The enterprise’s product categories include regular, fine, after-soaking oral, directly-oral and advanced traditional Chinese medicine piece (TCMP) products as well as TCM homologous supplements. These include ShaRen, JueMingZi, QingGuo, RenShen, DingXiang, WuWeiZi, HuangShuKuiHua, ChuanBeiMu, HongQuMi, ChaoSuanZaoRen, XueJie, LuXueJing, XiaTianWu, CuYanHuSuo, JiangXiang, SuMu, HongQi, SanQiFen and ChenXiang.

The firm recently entered into an agreement to acquire Jiangsu Pharmaceutical Co. The move will integrate the Suxuantang traditional brand with the new mode of retail used by Jiangsu and bring in more opportunities for strategic investment for both companies and also fuel sales growth.

China SXT Pharmaceuticals (SXTC), closed Friday's trading session at $3.97, up 97.5124%, on 31,304,534 volume. The average volume for the last 3 months is 25,716 and the stock's 52-week low/high is $1.651/$17.00.

Southern Energy (SOUTF)

We reported earlier on Southern Energy (SOUTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Southern Energy Corp (OTCQX: SOUTF) (CVE: SOU) (LON: SOUC) (FRA: 0M1) is an oil and natural gas exploration and production firm.

The firm has its headquarters in Calgary, Canada and was incorporated in 1945, on November 9th. Prior to its name change in January 2019, the firm was known as Standard Exploration Limited. It operates as part of the oil and gas E&P industry, under the energy sector. The firm serves consumers in Canada and the United States.

The company operates through the Southern Power, Traditional Electric Operating Companies, and Southern Company Gas segments. Its primary source of income is the petroleum and natural gas revenue.

The enterprise has three assets in the Mississippi Interior Salt Basin (MISB), which include the Mechanicsburg, Gwinville, and Mount Olive East fields. It operates and owns a working interest in over 12,000 hectares held by the production acres of land in the Gwinville field. It operates and owns a working interest in approximately 3,450 held by the production acres of land in the Mechanicsburg field. The enterprise operates and owns a working interest in over 1,415 held production acres of land in the Mount Olive East field. It owns and operates production from a number of other fields in the MISB within 40 miles of Gwinville, including Greens Creek and Williamsburg South gas fields, along with minor oil production from the Magee field.

The firm recently announced its latest financial results, with its CEO noting that they remained committed to going after organic growth opportunities in its portfolio and growing the business with its new and longstanding shareholders.

Southern Energy (SOUTF), closed Friday's trading session at $0.16108, up 0.42394%, on 90,000 volume. The average volume for the last 3 months is 38,088 and the stock's 52-week low/high is $0.1495/$0.6047.

Great Pacific Gold (FSXLF)

InvestorPlace, QualityStocks and The Online Investor reported earlier on Great Pacific Gold (FSXLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Great Pacific Gold Corp (OTCQX: FSXLF) (CVE: GPAC) (FRA: V3H) is a junior exploration firm that is focused on acquiring and exploring for gold and copper deposits in Australia and Papua New Guinea.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2019, on July 22nd. Prior to its name change in September 2023, the firm was known as Fosterville South Exploration Limited. It operates as part of the gold industry, under the basic materials sector. The firm serves consumers around the globe.

The company operates a significant 2,166km2 mineral exploration land package in Papua New Guinea (PNG). The land package has 3 main projects, which include three licenses (ELs) and multiple exploration license applications (ELAs). It includes both early-stage and advanced-stage exploration targets with epithermal vein and porphyry-style mineralization potential present. The projects include Arau, Kesar Creekand Wild Dog. The Arau Project comprises of one granted exploration license, EL 2651; and one exploration license application, ELA 2715, located in the Kainantu region. The Kesar Creek Project includes one granted exploration license, EL 2711, and is located 10km west of the K92 Gold Mine owned and operated by K92 Mining Inc. The Wild Dog Project comprises of one granted exploration license, EL 2761; and one exploration license application, ELA 2516, located on the island of New Britain and about 50km southwest of Rabaul and Kokopo, PNG.

The enterprise, which recently concluded its acquisition of Wild Dog Resources Inc., remains committed to diversifying its portfolio with high-quality gold and copper assets and growing through the execution of its well thought out drill programs. This may in turn help create additional value for its stakeholders.

Great Pacific Gold (FSXLF), closed Friday's trading session at $0.6983, off by 1.2445%, on 40,377 volume. The average volume for the last 3 months is 25,001 and the stock's 52-week low/high is $0.22/$0.739.

Macarthur Minerals (MMSDF)

We reported earlier on Macarthur Minerals (MMSDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Macarthur Minerals Limited (OTCQB: MMSDF) (ASX: M10) (CVE: MMS) (FRA: MMLB) is an exploration and development firm that is focused on exploring for and evaluating mineral resource properties.

The firm has its headquarters in Milton, Australia and was incorporated in 2002, on December 2nd by Kenneth Talbot. Prior to its name change in July 2005, the firm was known as Macarthur Diamonds Ltd. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm mainly serves consumers in Australia.

The company primarily explores for gold, lithium, nickel and iron ore deposits. It holds interests in 3 iron ore projects in the Yilgarn region of Western Australia. The Lake Giles Iron Project mineral resources include the Ularring hematite resource (approved for development) comprising Indicated resources of approximately 54.5 million tons and Inferred resources of over 26 million tons; and the Lake Giles magnetite resource of approximately 53.9 million tons (Measured), 218.7 million tons (Indicated) and 997 million tons (Inferred). The Lake Giles Iron Project also contains Proven Ore Reserves of 51.9Mt and Probable Ore Reserves of 184.7Mt. The company also owns mineral rights for iron ore on two tenements located in the Pilbara region of Western Australia, Strelley Gorge - E45/4735 and Tambourah North - E45/5324. In addition, the company has lithium brine interests in the Railroad Valley, Nevada, USA.

The firm is focused on advancing exploration efforts at its mines and generating additional value for its shareholders. This may in turn encourage additional investments into the firm and bolster its overall growth.

Macarthur Minerals (MMSDF), closed Friday's trading session at $0.08724, even for the day, on 465,750 volume. The average volume for the last 3 months is 53,529 and the stock's 52-week low/high is $0.0738/$0.2098.

Medicine Man Technologies (SHWZ)

MarketBeat reported earlier on Medicine Man Technologies (SHWZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Medicine Man Technologies Inc. (OTCQX: SHWZ) is a vertically integrated multi-state cannabis operator focused on cultivating, manufacturing, distributing and retail selling cannabis and cannabis-related products in New Mexico and Colorado.

The firm has its headquarters in Denver, Colorado and was incorporated in 2014, on March 20th by Andrew Williams. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm serves consumers in North America.

The company operates as Schwazze, through the Wholesale, Retail, and Other segments. The Wholesale segment manufactures, cultivates, and sells wholesale cannabis and non-cannabis products. The Retail segment includes retail locations for sale of cannabis products. On the other hand, the Other segment includes the general corporate operations not categorized as retail or wholesale, and revenue from in-store advertisements and certain vendor operations. The company owns and operates 5 cultivation facilities, 2 manufacturing facilities, and 42 retail dispensaries.

The enterprise provides concentrates, loose flower, edibles, pre-rolls, infused beverages, topicals, and other associated cannabis products produced by cannabis vendors; and cannabis and non-cannabis products. It operates retail cannabis dispensaries under the R. Greenleaf, Emerald Fields, and Star Buds brand names. In addition to this, the enterprise offers licensing, facility design, and facility management services; and Three A Light publication. Further, it sells hydroponics and indoor gardening supplies through its retail and online stores.

The firm recently announced its latest financial results, with its CEO noting that they remained focused on further enhancing the customer experience, expanding their wholesale business in New Mexico, and enhancing its geographic footprint as well as its brand portfolio. This may positively influence revenues into the firm as well as its overall growth.

Medicine Man Technologies (SHWZ), closed Friday's trading session at $0.6097, up 3.339%, on 125,458 volume. The average volume for the last 3 months is 38,598 and the stock's 52-week low/high is $0.48/$1.595.

Trigon Metals (PNTZF)

We reported earlier on Trigon Metals (PNTZF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Trigon Metals Inc. (OTCQB: PNTZF) (CVE: TM) (FRA: TZU2) is an exploration and development firm that is focused on acquiring, exploring for, developing and maintaining mines and mineral properties on the African continent.

The firm has its headquarters in Toronto, Canada and was incorporated in 1997, on December 11th. Prior to its name change in December 2016, the firm was known as Kombat Copper Inc. It operates as part of the copper industry, under the basic materials sector. The firm mainly serves consumers in Canada.

The company primarily explores for copper, lead, and silver deposits in mine-friendly African jurisdictions. It has operations in Namibia and Morocco. In Namibia, it holds an 80% interest in its flagship project, the Kombat Mine Property, which comprises of 5 mining licenses in the Otavi Mountainlands on the Northern Platform Margin of the Damara Orogenic Belt. This area in Northern Namibia is generally recognized for its high-grade copper deposits, which cover approximately 1,219 hectares and prospecting license covering 6,671 hectares. In Morocco, the company is the holder of the Silver Hill and Addana projects, highly prospective copper and silver exploration projects. Silver Hill is a 16km2 property located in the Anti-Atlas region.

The firm recently entered into a definitive share exchange agreement to acquire a 100% equity interest in Privco, a private arms-length firm that holds an option to earn up to a 70% stake in the Kalahari Copperbelt Project. This move will expand its copper portfolio with this high-potential project in Namibia while also opening it up to new growth and investment opportunities.

Trigon Metals (PNTZF), closed Friday's trading session at $0.1835, up 3.9366%, on 5,330 volume. The average volume for the last 3 months is 75.04M and the stock's 52-week low/high is $0.1004/$0.2087.

Nikola Corporation (NKLA)

Green Car Stocks, Schaeffer's, InvestorPlace, QualityStocks, StockEarnings, MarketClub Analysis, StocksEarning, MarketBeat, The Street, Kiplinger Today, Trades Of The Day, Early Bird, StreetInsider, Daily Trade Alert, The Online Investor, Zacks, Cabot Wealth, GreenCarStocks, Louis Navellier, CNBC Breaking News, Wealth Insider Alert, Investopedia, INO Market Report, MarketTamer, InvestorsUnderground, StockMarketWatch, Green Energy Stocks, AllPennyStocks, The Wealth Report, DividendStocks, Daily Profit, Outsider Club and Prism MarketView reported earlier on Nikola Corporation (NKLA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Most American automakers have pledged to electrify their vehicle lineups as part of global efforts to curb greenhouse gas emissions and mitigate climate change. Battery electric vehicles are ideal transportation for a green economy because they run on electricity rather than fossil fuels and do not produce any emissions at the tailpipe.

Under the notion that electric vehicles will be the dominant form of vehicular transportation over the next couple of decades, car makers have invested hundreds of millions of dollars into electrification initiatives. However, consumers seem to be more interested in hybrid vehicles rather than battery electric cars.

Edmunds.com reports that American drivers have purchased more than a million hybrids and 148,000 plug-in hybrids in 2023 alone, 76% more than they bought over the same period in 2022. Hybrids are becoming increasingly popular among American drivers because they tend to be cheaper than electric cars and offer most of the same benefits without the hassles associated with owning an electric car.

In addition, hybrids are more ecofriendly than conventional cars but do not require that drivers change their lifestyles to accommodate their new vehicles. Furthermore, their affordability means they are available to a greater portion of the market, especially younger drivers who tend to be more interested in EVs but aren’t as financially secure as older drivers. Numerous polls show that most consumers are wary of battery electric cars due to the lack of public charging infrastructure and astronomical purchase costs.

Although electric vehicle sales hit a record of a million units sold in 2023, year-over-year growth has begun to slow down. EV demand has been especially low in recent months as premium EV prices coupled with high-interest rates and rising living costs made electric cars even more costly. American car makers are also facing increasing competition from Chinese companies that are using state subsidies to massively discount their EV offerings and price out foreign automakers from their own markets.

With consumer interest in battery electric vehicles faltering, some car makers are scaling back their ambitious plans to develop new electric cars or build battery manufacturing facilities. Furthermore, some companies are now looking at hybrids as an avenue for attracting the average American driver.

Ford, the second-best-selling hybrid producer in the country, expects to manufacture enough hybrids to quadruple its sales in five years, and General Motors has revealed that it is considering bringing hybrids back to the American market after it abandoned the concept several years ago.

Other companies in the space, including Nikola Corporation (NASDAQ: NKLA), may have to weigh whether adding hybrids to their lineups could be a viable strategy or not in the long-term.

Nikola Corporation (NKLA), closed Friday's trading session at $0.8748, off by 1.3754%, on 85,283,023 volume. The average volume for the last 3 months is 6.179M and the stock's 52-week low/high is $0.521/$3.71.

Hecla Mining Company (HL)

MarketClub Analysis, SmarTrend Newsletters, Schaeffer's, QualityStocks, InvestorPlace, StocksEarning, MarketBeat, Wyatt Investment Research, Lebed.biz, Top Pros' Top Picks, TopStockAnalysts, StreetAuthority Daily, INO.com Market Report, DividendStocks, Money Morning, Zacks, The Street, Marketbeat.com, Jason Bond, StockEarnings, Kiplinger Today, Daily Trade Alert, Wall Street Grand, StreetInsider, Today's Financial News, Trades Of The Day, TradersPro, INO Market Report, StockOodles, TheStockAdvisors, Streetwise Reports, The Wealth Report, Gryphon Digest, Stockhouse, SureMoney, MiningNewsWire, Penny Detectives, National Inflation Association, TradingAuthority Daily, PennyStockLive, Darwin Investing Network, Options Elite, ChartAdvisor, Penny Sleuth, Profit Confidential, ProfitableTrading, Wall Street Daily, TraderPower, The Growth Stock Wire, CustomerService, Traders For Cash Flow, TradingMarkets, Greenbackers, Forbes, DrStockPick, Wealth Insider Alert, Daily Wealth, Daily Markets, Investopedia, CRWEWallStreet, CRWEPicks, CRWEFinance, Weiss Research, BestOtc, Barchart, WealthMakers, The Online Investor, PennyToBuck, MonsterStocksPicks, Money and Markets, Residual Income Report, Rockwell Trading, SmallCapVoice, Stock Stars, Investing Futures, StockHotTips, PennyOmega, Trade of the Week, InvestorIntel, InvestorGuide, Investor Update, Investor Guide, AllPennyStocks, Investing Lab and MarketArmor.com reported earlier on Hecla Mining Company (HL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

For centuries, silver has been used as a store of value, similar to other precious metals. Silver is used in various industries, with one of its primary uses being in solar energy as a conductor for photovoltaic cells. The metal also has a variety of technological applications, including its use in 5G connectivity. It is expected that silver’s industrial demand will continue to grow, particularly as the shift to renewable sources of energy gains traction.

In recent times, this industrial metal has also become a popular option for investment. However, knowing the right quantity of silver to include in an investment portfolio can be hard. Below, we look at ways to include the metal in one’s diversified portfolio as well as investment options for silver.

When it comes to investing in silver, experts recommend that precious metal investments range between 5% to 10% in a diversified portfolio. This is a general recommendation, however, and investors may tweak this, depending on their investment goals.

Investing options are often categorized into digital silver and physical silver. Digital silver primarily includes digital tokens and exchange-traded funds (ETFs) while physical silver includes bullion coins, rounds and bars.  The two options have their own pros and cons, with digital silver affording the investors liquidity and convenience of electronic trading. Unlike physical silver, digital silver is stored in a brokerage account or a digital wallet and can be sold and bought easily and quickly. This makes it a good option for investors planning to trade the metal regularly.

On the other hand, physical silver is a tangible asset that can be held in possession as well as be stored. Owning physical silver may also offer investors a sense of security and satisfaction from legally owning an asset.

Investors who would like to own both physical and digital silver can do so through several companies that offer these services, such as Kinesis Silver. It is important to note that the choice between digital and physical silver boils down to an individual’s investment goals as well as their personal preferences.

In the event of a financial crisis, most traditional investments such as bonds and stocks decline in value, which makes it important to include a safe-haven asset such as silver in one’s diversified portfolio. Silver, similar to all other safe-haven assets, protects investors from market volatility and inflation, helping preserve purchasing power as well as protect wealth.

It should be noted, however, that the metal’s value can also be impacted by economic downturns, as its demand in industrial uses may decrease. Such changes also affect stocks of the metal’s producers, such as Hecla Mining Company (NYSE: HL), in the same way that tailwinds such as instability in key mining regions result in price hikes due to concerns about supply sustainability.

Hecla Mining Company (HL), closed Friday's trading session at $4.81, off by 2.4341%, on 5,096,882 volume. The average volume for the last 3 months is 52.081M and the stock's 52-week low/high is $3.55/$7.00.

Marathon Digital Holdings Inc. (MARA)

MarketClub Analysis, InvestorPlace, Schaeffer's, QualityStocks, INO Market Report, StockMarketWatch, MarketBeat, StocksEarning, StockEarnings, TradersPro, BUYINS.NET, The Online Investor, Lebed.biz, Zacks, Trades Of The Day, TraderPower, Early Bird, The Street, Daily Trade Alert, Marketbeat.com, InvestorsUnderground, BillionDollarClub, Wall Street Mover, TopPennyStockMovers, PoliticsAndMyPortfolio, Investment House, Wealth Insider Alert, StreetAuthority Daily, Kiplinger Today, FeedBlitz, Eagle Financial Publications, AllPennyStocks, Barchart, 360 Wall Street, RedChip, CryptoCurrencyWire, DreamTeamNetwork, Lance Ippolito, StreetInsider, Promotion Stock Secrets, Stock Analyzer, Stock Beast, Street Insider, StockOodles and Rick Saddler reported earlier on Marathon Digital Holdings Inc. (MARA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

U.S. Securities and Exchange Commission (SEC) chair Gary Gensler sounded a cautionary note about the state of the cryptocurrency landscape on the social media platform X last week. Gensler expressed concern over the widespread lack of compliance in the crypto space, emphasizing the detrimental impact it has on investor confidence. He highlighted the unfortunate situation where numerous individuals have suffered losses and find themselves queuing up in bankruptcy courts with limited recourse.

Accompanying his X post was a video clip from a recent CNBC appearance where Gensler discussed the prevailing issue of noncompliance in the crypto industry, specifically in relation to securities laws. He stressed that these laws are not merely a formality but serve a dual purpose—providing investors with essential information for decision making and safeguarding them against manipulation and fraudulent activities.

Gensler reiterated that the challenges extend beyond the SEC’s jurisdiction, pointing out violations of regulations set by bodies such as the Financial Crimes Enforcement Network (FinCEN) and the Commodity Futures Trading Commission (CFTC). In a vivid metaphor, Gensler characterized the crypto landscape as the “Wild West” with global ramifications. He underscored that the problem isn’t isolated to a few bad actors but permeates the entire industry, making it particularly challenging for those operating in good faith to compete on a level playing field.

Gensler’s X post prompted a response labeled “Readers added context,” indicating the ongoing efforts of crypto entities, such as Coinbase, to seek clarity regarding SEC compliance guidance. Some users mocked Gensler’s statements, with one user celebrating the perceived undermining of Gensler’s credibility, while another attributed the erosion of confidence in the SEC to Gensler’s leadership, except for a specific entity, Prometheum. A third user raised concerns about Gensler’s alleged ties with certain individuals in the industry.

Criticism of the SEC and Gensler, under his leadership, has been mounting, with accusations of an overly enforcement-focused approach to crypto industry regulation. Calls for his removal as SEC chairman have even manifested in a bill currently before Congress. Meanwhile, the SEC is actively evaluating 13 applications for spot Bitcoin exchange-traded funds (ETFs), with expectations of approval for multiple ones by Jan. 10, 2024. The timing and nature of Gensler’s warnings have sparked speculation and debate within the X community, adding another layer to the ongoing scrutiny of regulatory actions in the crypto space.

What industry players such as Marathon Digital Holdings Inc. (NASDAQ: MARA) would appreciate are clear regulations to guide their actions rather than the current approach of “regulation by prosecution.”

Marathon Digital Holdings Inc. (MARA), closed Friday's trading session at $23.49, off by 16.4354%, on 144,949,654 volume. The average volume for the last 3 months is 2.907M and the stock's 52-week low/high is $3.1273/$31.30.

SNDL Inc. (SNDL)

InvestorPlace, Schaeffer's, StockEarnings, StocksEarning, QualityStocks, MarketBeat, Trades Of The Day, Daily Trade Alert, BUYINS.NET, The Street, Kiplinger Today, The Online Investor, StreetInsider, Early Bird, CNBC Breaking News, FreeRealTime, Investopedia, MarketClub Analysis, StockMarketWatch and MarketClub reported earlier on SNDL Inc. (SNDL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent study published in the “Endometriosis and Uterine Disorders” Journal has unveiled promising results regarding CBD-infused tampons for alleviating menstrual pain and severe cramps. The study’s authors posit that these CBD-infused tampons may present a more favorable option with fewer side effects compared to traditional anti-inflammatory medications, offering a parallel pain-relieving impact.

The research team, comprised of six researchers, noted the following in their report: “The outcomes suggest that CBD-infused tampons hold potential as an effective solution for managing menstrual pain.” They emphasized the necessity for further exploration and research into the product, asserting its potential contribution to addressing primary dysmenorrhea, a condition characterized by painful muscle cramps and spasms affecting between 50% and 90% of menstruating women.

The study examined the relationship between CBD, CB2 and CB1 receptors, claiming that because these receptors are extensively dispersed throughout uterine tissue, they provide an ideal target for the localized administration of cannabinoids to reduce pain. A randomized, placebo-controlled methodology was used to conduct the study, and participants were not informed whether they were using a regular or CBD-infused tampon. Participants self-reported their pain thresholds and general levels of satisfaction.

The study group carefully investigated a number of factors, such as systemic toxicity, vaginal irritation, material-mediated pyrogenicity, sensitization, and possible risk of toxic shock syndrome. They confirmed that every test was passed with success, demonstrating the safety of tampons infused with CBD.

Regarding pain alleviation, the report indicated a noteworthy percentage change, reaching 100% in the last menstruation days. Additionally, the study demonstrated a statistically significant decrease in discomfort during particular days of the menstrual cycle, two hours after tampon application.

Although fewer than 5% of participants reported experiencing irritation as a result of using CBD-infused tampons, between 37% and 40% reported an improvement in their vaginal dryness. Two patients reported vertigo while using the product; however, the symptoms cleared promptly without the need for medical treatment after removing the tampon.

The study’s lead author, Valentina Milanova, who also serves as CEO of Daye, a gynecological research company that claims to offer the first CBD-infused tampon worldwide, stated that the observed alleviation of primary dysmenorrhea throughout the menstrual cycle supports the potential effectiveness of CBD-infused tampons. All authors have financial ties to Daye’s parent company, Anne’s Day Ltd., based in London.

The authors did note the study’s shortcomings, particularly its small sample size, and urged future research and improvements to the research design, including the use of a crossover design to collect full pain data.

Cannabis research is still relatively in its infancy, but as the years go by, much more is likely to be known about the health and wellness benefits of the marijuana products currently commercialized by entities such as SNDL Inc. (NASDAQ: SNDL).

SNDL Inc. (SNDL), closed Friday's trading session at $1.64, even for the day, on 4,030,283 volume. The average volume for the last 3 months is 11,109 and the stock's 52-week low/high is $1.25/$2.48.

Community Redevelopment Inc. (CRDV)

QualityStocks and OTC Stock Review reported earlier on Community Redevelopment Inc. (CRDV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Community Redevelopment (OTC: CRDV), a significant player in the D.C. metro real estate market, has appointed a new company president. Phil Sands, a seasoned veteran in the investment community, was named the new president and a member of the company’s executive management team. In his new role, Sands will focus on oversight of the company's investment agenda to secure needed capital for continued and stable growth and will work with CEO Richard Balles to comanage the company’s strategic direction and represent CRDV’s corporate interests with key regulatory entities. Sands has gained impressive leadership experience in both the public and private sectors, having served as CEO, interim CFO, director and president of a variety of companies in both spaces; he has also been instrumental in helping companies raise millions of dollars in capital. “I am excited to build CRDV with someone of the caliber of Phil Sands,” said Community Redevelopment chair and CEO Richard Balles in the press release. “He is a true professional of the highest quality and we are fortunate to have him as our president.”

To view the full press release, visit https://ibn.fm/3Amgb

About Community Redevelopment Inc.

Community Redevelopment is a full-service, real-estate company with a management team that has extensive experience in acquiring, developing, constructing and managing high-quality multifamily and retail properties. The company is focused on all aspects of the urban real-estate development cycle including land development, design build, property operations and site redevelopment. In addition to the ownership of its operating property portfolio, Community Redevelopment plans to develop and build desirable properties for its own account and/or through joint ventures with affiliated and unaffiliated partners. For more information about the company, please visit www.CommunityRedevelopment.net.

Community Redevelopment Inc. (CRDV), closed Friday's trading session at $0.1, even for the day, on 5,022 volume. The average volume for the last 3 months is 274,306 and the stock's 52-week low/high is $0.0005/$0.10.

TerrAscend Corp. (TSNDF)

QualityStocks, InvestorPlace and Cabot Wealth reported earlier on TerrAscend Corp. (TSNDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last week, a senator in Florida introduced a measure that would allow licensed medical-cannabis businesses to claim tax deductions. At the moment, legal marijuana businesses in the country aren’t allowed to claim deductions because of section 280E of the IRS code, which bars deductions from being claimed for illicit substances.

Section 280E prohibits businesses from deducting business expenses from gross income linked to the trafficking of Schedule I or II drugs. Currently, marijuana is still classified under Schedule I of the Controlled Substances Act. The measure, filed by GOP senator Ana Maria Rodriguez, would add Florida to a growing list of other states that have established tax parity for the marijuana industry.

The bill would amend the state’s tax code by permitting medical-marijuana operators to claim deductions in amounts equal to expenditure eligible to be claimed as federal income tax deductions. It should be noted that this measure would only extend relief to state medical-marijuana businesses.

Other states that have taken similar steps include Pennsylvania, whose House passed a sweeping tax reform measure in October containing language offering state relief to medical-cannabis businesses. The proposal hasn’t been fully accepted by GOP members, who see it as a giveaway by Democrats to the marijuana industry.

In November, New York’s governor signed a measure offering tax relief to cannabis businesses in the state. This comes after a budget measure enacted in 2022 included provisions to broadly permit state-level marijuana business tax deductions. Maine’s governor had, in August, signed a resolution decoupling state tax from the federal policy for marijuana businesses.

Earlier in June, Connecticut’s governor signed a budget measure that included provisions offering state-level tax relief to licensed cannabis businesses as a workaround for the industry. That same month, the governor of Illinois signed a budget measure that included provisions permitting licensed cannabis businesses to claim tax deductions that they’re currently barred from utilizing under Section 280E. In May, the governor of New Jersey also signed a bill that would permit licensed cannabis businesses to deduct some expenses on their tax returns as a partial fix.

At the congressional level, Representative Earl Blumenauer reintroduced a measure that would amend the code to permit state-legal cannabis businesses to claim tax deductions that are available to businesses operating in other industries. In an interview, Blumenauer explained that allowing state-legal businesses to fully deduct their business expenses would result in additional revenue collection because individuals would comply with the law.

This growing wave of states seeking ways to give the cannabis industry tax relief at the state level could afford enterprises such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) a breather that allows them to bring more innovative products to the market.

TerrAscend Corp. (TSNDF), closed Friday's trading session at $1.63, off by 3.5503%, on 201,285 volume. The average volume for the last 3 months is 150 and the stock's 52-week low/high is $1.00/$2.3407.

The QualityStocks Company Corner

Diamond Lake Minerals Inc. (OTC: DLMI)

The QualityStocks Daily Newsletter would like to spotlight Diamond Lake Minerals Inc. (OTC: DLMI).

Utah-based Diamond Lake Minerals is building a groundbreaking model for digital asset investment that focuses on vertically integrated, industry-agnostic subsidiaries as stocks that happen to have tokenized security elements

DLMI's strategy is to attract digital asset novices and skeptics through a regulated environment gateway, to help them participate in the growing opportunities for a strong tech-based market

Expectations that the Securities and Exchange Commission will approve a spot bitcoin ETF in the next few weeks, as well as policy-makers' indications that inflation worries have eased, are helping to drive new optimism for the market

Diamond Lake has seen its market capitalization rise to over $100 million in a few months' time as new leadership has turned the company toward its new focus on tokenized securities

Recent indications by monetary policy makers in the United States that inflation worries are waning, coupled with expectations that the Securities and Exchange Commission ("SEC") will approve a spot bitcoin ETF shortly after New Year's Day, are helping to drive a "perfect storm of positive tailwinds" for new digital currency adoption by investors, according to Fundstrat Global Advisors VP of Digital Asset Strategy Sean Farrell (https://ibn.fm/P81b0). Amid the historical differences of opinion over digital tokens, multi-strategy operating company Diamond Lake Minerals (OTC: DLMI) is building confidence in its approach to acquiring and establishing numerous industry-agnostic subsidiaries. Direct investment in DLMI shares represents a link to having ownership in all divisional products, and is a convenient gateway for digital asset entry by uncertain investors who may be unwilling or unprepared to take on the challenge of navigating the complexities of the digital token market.

Diamond Lake Minerals Inc. (OTC: DLMI) is a multi-strategy operating company offering traditional investors an entry point to the future of digital securities. The company’s goal, through its established M&A roadmap, is to responsibly innovate and develop promising businesses that are likely to benefit from the ongoing shift toward digital assets. Through this approach, Diamond Lake Minerals provides traditional investors an opportunity to gain exposure to the emergence of regulated digital securities through a more familiar investment vehicle – the purchase of stock.

Founded in 1954 and headquartered in Salt Lake City, Diamond Lake Minerals is positioning itself as a leader in the digital asset and security token space. The company’s mission is to bring back to the public markets timeless business principles focused on healthy, sustainable growth and strong earnings with a goal of creating value for stakeholders in the modern digital world.

Diamond Lake Minerals believes the future of financial markets is set to be revolutionized by tokenization. Tokenization refers to the use of digital assets that can be traded via protocols with instantaneous settlement and reduced fees, eliminating the need for traditional clearing or settlement processes. Beyond efficiency, the emerging landscape emphasizes transparency, liquidity and security in asset management and investment.

With the backing of Esposito Intellectual Enterprises and its 20+ years of experience, Diamond Lake Minerals has access to the expertise of 110+ companies and 200+ joint ventures, along with knowledge spanning 25+ industries. The company is creating a vertically integrated ecosystem that encompasses various high-growth sectors. This integration aims to maximize operational efficiencies and profitability across all business units.

Products & Services Portfolio

Diamond Lake Minerals, guided by its strategic partnerships and future roadmap, envisions a diverse portfolio across multiple industries, as shown in the overview below. The company is poised to redefine the conglomerate model for the 21st century, with a focus on vertical integration, digital securities and sustainable growth.

Its target market segments include:

  • Fashion: DLMI seeks stakes in brands blending timeless aesthetics with tech influences.
  • Beauty: DLMI eyes partnerships with innovators elevating beauty through sustainable practices.
  • Real Estate: DLMI aims for interests in ventures modernizing property transactions via blockchain.
  • Hospitality: DLMI’s vision includes associations with enterprises enhancing guest experiences via tech integration.
  • Liquor: DLMI aspires to collaborate with unique distillers merging tradition and innovation.
  • IoT: DLMI intends to invest in solutions seamlessly connecting the digital and physical worlds.
  • Wireless: DLMI envisions stakes in wireless tech optimizing global communication.
  • Technology: DLMI plans to back pioneers driving the next tech revolution.
  • Maritime: DLMI seeks partnerships in maritime solutions emphasizing green initiatives.
  • Aviation: DLMI’s strategy includes holdings in aviation innovators focusing on efficiency.
  • Aerospace: DLMI aims to support ventures pushing boundaries in space exploration.
  • Education: DLMI collaborates with platforms revolutionizing learning through tech.
  • Charity: DLMI eyes alliances with charitable entities leveraging transparency via blockchain.
  • Healthcare: DLMI foresees investments in healthcare tech personalizing patient care.
  • TV: DLMI intends stakes in TV platforms innovating content delivery.
  • Film: DLMI aspires to support filmmakers merging storytelling with immersive tech.
  • Music: DLMI plans interests in music ventures amplifying artists through digital platforms.
  • Entertainment: DLMI targets stakes in platforms redefining entertainment paradigms.
  • IP: DLMI envisions collaborations safeguarding intellectual properties via tech solutions.
  • Data Management: DLMI seeks ventures optimizing data utilization and insights.
  • Data Storage: DLMI’s roadmap includes alliances with secure data storage solutions.
  • Streaming: DLMI intends to back streaming platforms prioritizing user experience.
  • Real World Assets: DLMI eyes investments translating tangible assets into digital value.
  • Gold & Silver: DLMI aims for stakes in platforms digitizing precious metal trading.
  • Sports: DLMI envisions collaborations enhancing sports experiences via tech integration.
  • Sports Technology: DLMI seeks ventures revolutionizing athlete performance and fan engagement.
  • Water: DLMI plans to back solutions ensuring water sustainability and accessibility.
  • Water Treatment: DLMI targets investments in eco-friendly water purification technologies.
  • Animation: DLMI eyes stakes in animation houses blending art with cutting-edge tech.
  • Studio Production: DLMI’s vision includes support for studios transforming content creation.
  • Consumer Products: DLMI seeks partnerships with brands prioritizing consumer-centric innovations.
  • Collectables: DLMI envisions collaborations with platforms digitizing unique collectibles.
  • Digital Assets: DLMI aims to invest in ventures maximizing the potential of digital ownership.
  • Web3: DLMI aspires to back pioneers ushering in the decentralized web era.
  • Identity Management: DLMI eyes solutions prioritizing user identity security in the digital space.
  • Media & Journalists: DLMI seeks alliances promoting unbiased reporting and content democratization.
  • Metaverse: DLMI envisions stakes in ventures crafting immersive virtual universes.
  • Space Economy: DLMI targets investments in ventures monetizing space exploration.
  • Modular Homes: DLMI plans interests in solutions revolutionizing home construction.
  • Financial Technology: DLMI seeks partnerships modernizing financial transactions.
  • Gaming: DLMI aims to back game developers enhancing user immersion.
  • Travel: DLMI eyes collaborations transforming travel experiences through tech.
  • Health & Wellness: DLMI’s strategy includes investments in holistic health tech solutions.
  • Augmented Reality: DLMI envisions stakes in AR platforms blurring reality and digital.
  • AI: DLMI seeks to support AI innovations humanizing tech interactions.
  • Esports: DLMI targets investments in platforms amplifying esports experiences.
  • Construction: DLMI plans to back ventures modernizing construction practices.
  • Virtual Reality: DLMI intends stakes in VR platforms offering alternate realities.
  • Retail Tech: DLMI envisions collaborations digitizing retail experiences.
  • Biotechnology: DLMI seeks ventures pushing boundaries in biotech innovations.

Market Opportunity

According to Diamond Lake Minerals’ business plan executive summary, the market for digital securities is projected to grow from $10 billion in 2022 to $1 trillion by 2028, a CAGR of 45% for the forecast period.

The global blockchain market value is expected to grow from an estimated $3 billion in 2020 to $39.7 billion by 2025, marking a CAGR of 67.3% for the period. Valued at $2.28 billion in 2021, the Security Token Offerings market is projected to grow at a CAGR of 19%. This growth is expected to be driven by the rising adoption of tokenization and the increasing prominence of STOs, especially in North America.

In addition, the global investment management market is projected to grow from a value of $100 trillion in 2020 to $178 trillion by 2025, recording a CAGR of 7.2% over the period.

Management Team

Brian J. Esposito is CEO of Diamond Lake Minerals. As founder and CEO of Esposito Intellectual Enterprises LLC, he brings over 20 years of diverse experience in sectors like manufacturing, technology, music and real estate, and is known for his global executive networking and balance sheet optimization skills.

Michael Reynolds is President and Director of Diamond Lake Minerals. With 35 years in private finance and M&A, he has been instrumental in growing companies like Herbalife through reverse acquisition, as well as elevating JB Oxford to $120 million in revenue. His expertise in operational management and business development ensures professional solutions for clients’ business interests.

Jon Karas is DLMI’s senior transaction and investment executive. As the CEO and co-founder of Akon Legacy Ventures, he structured, negotiated and closed numerous transactions focused on innovation and social impact in smart cities, blockchain, agriculture, mining and technology. He co-founded and led multiple companies in media and entertainment and was the driving force behind the development, financing and production of a broad range of film and television content.

Advisory Board

Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital and Chairman of SALT, brings to Diamond Lake Minerals unparalleled expertise in finance, technology and business strategy. He is expected to be instrumental in shaping DLMI’s strategic direction as the company continues to redefine the future of traditional and digital securities.

Larry Namer, Founder of E! Entertainment TV and President of Metan Global, boasts a remarkable career spanning more than half a century. He is an esteemed veteran of the entertainment industry, renowned for his influential contributions to cable television, live events, music and new media. He also leads LJN Media, a consulting firm known for its cross-industry expertise in technology, business and finance.

Andrew Fromm is a seasoned CEO and consultant with a focus on music publishing. He is known for his expertise in asset sales, songwriting and artist development. His extensive network extends beyond the music industry, showcasing his versatility and authority in the field.

Brandon Fugal is the Chairman of Colliers International in Utah and a former EY Entrepreneur of the Year. He has co-founded multiple ventures, including Coldwell Banker Commercial Advisors, Cypher, Axcend and Texas Growth Fund, and he is a recognized authority in real estate and entrepreneurship.

Michael Malik Sr. is a Detroit-based entrepreneur with a $750 million net worth, known for his pivotal role in legalizing gambling and developing major casino projects across the U.S., including Detroit’s MotorCity Casino and various Native American gaming ventures. He brings to Diamond Lake Minerals a wealth of experience and a proven track record in the gaming, sporting and entertainment industries spanning over five decades.

Raul Leal is an experienced CEO in the hospitality sector, known for his visionary leadership at SH Hotels & Resorts and former role at Virgin Hotels, where he secured over $500 million in funding and revolutionized guest experiences.

Agnes Budzyn, an accomplished entrepreneur and CEO of Bluedge Ventures, brings to the company a rich history in traditional finance and blockchain technology, serving on various global boards and committees. She has been recognized by the World Economic Forum and numerous institutions for her expertise and contributions to bridging legacy finance with emerging digital asset infrastructure.

Diamond Lake Minerals Inc. (OTC: DLMI), closed Friday's trading session at $4.9, even for the day. The average volume for the last 3 months is - and the stock's 52-week low/high is $0.35/$4.90.

Recent News

Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

Upstream, the revolutionary retail trading app for stocks and NFTs powered by Horizon Fintex and MERJ Exchange Limited, has experienced a pivotal year. A recent blog provided an overview of the app's biggest milestones for the company, which was launched this year. Key achievements throughout the year included the initiation of its dual-listing program, the evolution of a strategic media community, and the transition to digital collectibles aligning with its NFT methodology as well as the introduction of novel app features and the incorporation of educational resources. Upstream was born in 2023, and according to the blog, is the first regulated securities exchange powered by the Ethereum blockchain and the only direct-access exchange, allowing global investors access to international opportunities directly from their smartphones. "The past year has been significant for Upstream," the blog stated. "This period marks a substantial stride as we propel ourselves into what we perceive as the future of trading. . . . We are very proud of what the Upstream team has accomplished in 2023. We have launched multiple NFTs, had multiple dual listings go live, launched Upstream Up Close, and expanded our ecosystem with great minds in the industry. We expect to continue to grow in 2024 and introduce the future of trading to a global audience." To view the full blog, visit https://ibn.fm/V6VFV

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.

Products

Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & Issuance – ETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance Onboarding – KYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening Software – AMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management Tools – CustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App Technology – Open Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (merj.exchange), an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News

chart

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW)

The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

As the holiday shopping season draws to a close, more players in the e-commerce sector are reporting their earnings for the year. Below, we look at some of the major fulfillment vendors and retailers that announced earnings from their recent fiscal quarters. Amazon.com Inc. reported its highest operating income ever in its third quarter, raking in $143.1 billion. This increase represents a 343% growth, year over year (y-o-y). Walmart Inc.'s report shows that online sales in the United States rose by 24% for its 2023 fiscal third quarter. Over the same period, international e-commerce sales role 15% while global e-commerce dropped by 3%. Comparable sales in the United States rose by 4.9% while total revenue hit $160.8 billion, representing a 5.2% increase. The significance of e-commerce is undoubtedly going to increase in prominence, and those interested in carving out a share of this market need to niche down early enough. Platforms such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) provide ways to venture into healthcare e-commerce, which is one of the segments growing at a very high rate.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Alibaba.com Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Friday's trading session at $1.65, off by 3.5539%, on 34,324 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.2115/$4.26.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave (NYSE: QBTS), a leader in quantum computing systems, software and services and the world's first commercial supplier of quantum computers, commends the U.S. government's policy makers for including a quantum pilot program focused on near-term quantum computing applications in the National Defense Authorization Act ("NDAA"). The act was passed by Congress and signed into law by President Biden on December 22, 2023, establishing a program focused on near-term applications development to solve problems facing the Department of Defense ("DOD") including the Armed Forces. "We applaud Congress and the Administration for taking this critical step to accelerate the use of quantum to provide solutions for critical challenges facing DOD and our military," said Dr. Alan Baratz, CEO of D-Wave. "This bipartisan action also moves us closer to other global leaders who have already begun to build applications that benefit national security. D-Wave and its customers have already built several quantum-hybrid applications that can provide important benefits for the military, and we look forward to working with the government to advance this new pilot program." To view the full press release, visit https://ibn.fm/YFK9s

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Friday's trading session at $0.8801, off by 5.6193%, on 2,193,781 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3962/$3.20.

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology ("I&I") biological products and provision of boutique CDMO ("CDMO") services, has entered a definitive agreement for the immediate exercise of outstanding warrants. The agreement outlines the purchase of up to 2,606,552 American Depositary Shares ("ADSs"), with each ADS representing 400 ordinary shares. According to the announcement, exercise prices for the ADSs range from $1.16 to $5 per ADS and terms range from three years to five and one-half years. The company anticipates closing on the offering, which will be subject to customary conditions, about Jan. 3, 2024. Gross proceeds from the exercise of the warrants is projected to be an estimated $1.69 million before the deduction of placement agent fees and offering expenses. Scinai plans to use the funds from the offering for general working capital, R&D and general corporate purposes. To view the full press release, visit https://ibn.fm/79ONI

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Friday's trading session at $0.595399, off by 14.9308%, on 211,636 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.501/$3.60.

Recent News

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF)

The QualityStocks Daily Newsletter would like to spotlight Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF).

Appia Rare Earths & Uranium (CSE: API) (OTCQX: APAAF) (FSE: A0I0), a publicly traded Canadian company in the rare earth element and uranium sectors, has released an end-of-year letter for its shareholders. Signed by company president Stephen Burega, the letter reviewed the year's successes and achievements for the company. Highlights of the letter included the company's expansion into Brazil through an earn-in agreement to acquire up to 70% interest in the PCH Ionic Adsorption Clay project in Goiás State; the hiring of of SGS Geological Services, led by Marc-Antoine Leporte, to prepare a Mineral Resource Estimate ("MRE") on its high-grade Ionic Adsorption Clay REE Target IV project and a NI 43-101 technical report on the PCH Project; the company's key partnership with the Saskatchewan Research Council ("SRC") regarding its Alces Lake project in Saskatchewan; and a review of the two markets — rare earth elements ("REE") and uranium — that the company operates in. Burega noted that China's multiple bans on the export of various critical minerals, equipment and technology essential for constructing rare earth magnets, as well as technology for extracting and separating critical materials has exerted a positive influence on the growing demand for critical REEs and could act as a catalyst in strengthening the company's position in the global critical rare earths market; the letter also noted the increasing demand for uranium including the need for increased production to address the supply gap. "This past year has been extraordinary for the company," said Appia Rare Earths & Uranium president Stephen Burega in the letter. "Not only have we continued to move forward with our Canadian assets — with our priority focus on our flagship Alces Lake project in Northern Saskatchewan — but we have also expanded well beyond our Canadian borders into South America. . . . Our dedicated drilling programs have yielded promising results, further solidifying our position in the dynamic rare earth elements sector. We look forward to continued success on future drilling campaigns and the resulting data obtained from those exploration activities. As we navigate through these exciting developments in Brazil, Appia remains steadfast in its commitment to further develop our projects in Canada. We appreciate the support from our shareholders and communities of influence, and we anticipate a future marked by continued success and impactful milestones." To view the full press release, visit https://ibn.fm/PJVRb

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) is a mineral exploration company focused on exploration activities at its newly acquired Cachoeirinha rare earths project (“PCH Project”) in Brazil, as well as delineating high-grade critical rare earth elements (REE) and gallium at its Alces Lake property in Saskatchewan. Other properties in Appia’s portfolio include its Elliot Lake Property in Ontario’s historic mining camp, with a large NI 43-101 uranium and rare earths resource. Fully funded with over $5 million (CDN) in cash, no debt, aggressive exploration currently underway, and experienced management, Appia is progressing rapidly on multiple fronts in highly desired market sectors.

The company is headquartered in Toronto, Canada.

Projects

PCH Project-Brazil

The PCH project hosts REE mineralization in both ionic clays developed from the weathering of alkaline granites and in-situ rare earth mineralization associated with the underlying granite and a carbonatite intrusion to depths greater than 100 meters. Sampling data shows enrichment in rare earth minerals to depths of between eight meters and +30 meters.

In early 2023, Appia announced a definitive agreement to acquire a 70% interest in the PCH Project, which is 17,551 hectares in size and located in the Tocantins Structural Province of the Brasília Fold Belt, Goiás State, Brazil. It is classified as an alkaline intrusive rock occurrence with the potential for highly anomalous REE and Niobium mineralization.

The region around Iporá, a city located roughly 30 km from the PCH Project, has significant mineral exploration and mining activity and well-developed infrastructure.

In July 2023, Appia commenced an aggressive auger and reverse circulation (RC) drill campaign to delineate a potential resource estimate at the PCH project. Initial results at the site revealed significant exploration potential with impressive values that often surpass known ionic clay deposits in Brazil, particularly for the highly valuable heavy rare earths Terbium and Dysprosium.

The auger holes drilled at Target 4 have exhibited a range of total REE grades, ranging from 274 ppm to 16,648 ppm (1.66%), with an average of 1,291 ppm total REE. The valuable rare earths used in magnet applications – praseodymium, neodymium, terbium and dysprosium (Pr, Nd, Tb, and Dy) plus yttrium (Y) accounted for approximately 14% of total rare earths, reaching a maximum of 28.4%. Notably, the deposit also contains anomalous values of niobium and scandium, with average values of 736 ppm for Nb and 62 ppm for scandium in a composite sample from Target 4.

Heavy rare earths (HREEs) show maximum values of 1,624 ppm and average values of 1,291 ppm, primarily as terbium and dysprosium. Light rare earths (LREEs) show maximum values of 14,024 ppm (1.54%) with an average of 1,145 ppm. Neodymium and praseodymium, the main magnetic light rare earths, show respective maximum values of 3,131 ppm (Nd) and 885 ppm (Pr) and average values of 216 ppm (Nd) and 61.7 ppm (Pr). The overall HRRE/LREE ratio has a maximum of 39.5% and an average value of 16.67%.

“Appia is thrilled with the progress made and the promising results thus far,” CEO Tom Drivas stated in a news release. “The company remains committed to advancing its exploration plans, aiming to promptly gather significant data throughout the year, and to work towards estimating a maiden mineral resource in the coming months.”

Alces Lake Project – Saskatchewan

Appia’s Alces Lake project, located in northern Saskatchewan, encompasses some of the highest-grade total and critical REEs and gallium mineralization in the world, hosted within several surface and near-surface monazite occurrences that remain open at depth and along strike.

Following the company’s acquisition of additional new mineral claims in the area in February 2023, Appia’s Alces Lake claim block now totals 38,522 contiguous hectares (95,191 acres) – 100% owned by the Company.

Appia announced the completion of a NI43-101 technical report on the property in June 2023, providing an update on exploration previously reported in March 2021.The report is available on SEDAR under the company’s profile.

Extensive diamond drilling and geophysics surveys are underway to explore a more than 25-kilometer structural corridor. In July 2023, the company issued an update on its diamond drill program having completed the first phase of drilling at the project’s Magnet Ridge Zone to further test the extent of the mineralization to the south south-east (SSE). President Stephen Burega noted the presence of “continued mineralization at significantly thicker intercepts.”

As part of its 2023 exploration program at Alces Lake, Appia plans to target priority areas that extend SSE from the Wilson, Richard, Charles, Bell, Ivan, Dylan, Dante and AMP zones through the Magnet Ridge Zone and beyond, covering an area extending approximately 20 kilometers in length and 5 to 7 km in width. Appia will also undertake reconnaissance drilling on priority regional geological and geophysical targets in the Western Anomaly area.

Other Projects

  • Appia holds a total of 75,314 hectares (186,106 acres) of land on four uranium claim blocks in the prolific Athabasca Basin (Loranger, North Wollaston, Eastside and Otherside). Exploration plans for these properties are expected to be announced once permits are in hand.
  • Appia also has a 100% interest in 12,545 hectares (31,000 acres), with rare earth element and uranium deposits over five mineralized zones, in the Elliot Lake Camp, Ontario.

Market Opportunity

A report from Mordor Intelligence forecasts the global REE market is expected to grow from 168 million tons in 2023 to 206.25 million tons by 2028, marking a CAGR of 4.19% during the forecast period. The market is gradually improving following the economic and production restrictions of the COVID-19 pandemic.

Factors driving the market’s growth include high demand from emerging economies and the dependency of environmentally friendly technologies on rare earth elements.

According to UxC, one of the nuclear industry’s leading market research and analysis companies, the uranium market is rapidly becoming production-driven, where spot and long-term prices more closely correlate to the marginal cost of uranium production.

Although global reactor requirements are projected to be flat through 2024, UxC forecasts that significant demand growth from 2025 to 2040 will necessitate new production as resources are exhausted at several uranium projects. In addition, a large percentage of production exists in regions of the world with high geopolitical risk, which makes the market vulnerable to future disruptions and price volatility.

Management Team

Tom Drivas is CEO of Appia Rare Earths & Uranium Corp. He is an entrepreneur with over 30 years of experience in various industries, including over 20 years in the mineral resource industry. He is also currently a director of Romios Gold Resources Inc., a publicly traded company he founded in 1995.

Stephen Burega is President of Appia. He brings 16 years of management and operations experience in the mining and natural resources sectors. His extensive emerging markets background, along with a deep understanding of stakeholder management, social development and structured community engagement, position him well to lead Appia’s First Nations community engagements. He is also President and CEO of Romios Gold Resources which is focused on base and precious metal exploration in North America.

Frank van de Water is the company’s CFO. He holds CPA and CA designations and has been involved with international mining, metals and resource companies in North America, Latin America, Europe and Africa for more than 40 years.

Dr. Irvine R. Annesley, Ph.D., is VP Exploration at Appia. He is a licensed geoscientist (P.GEO.) and Professor in Economic (Mining and Mineral Exploration) Geology at École Nationale Supérieure de Géologie in France and an Adjunct Professor in Geology at the University of Saskatchewan. He has over 35 years of global exploration and applied research experience in uranium, gold and base metals exploration, most recently with Athabasca uranium explorer JNR Resources Inc.

Don Hains, P.Geo., is the company’s Consulting Geologist and Qualified Person Consulting Industrial Minerals Expert.

Antonio Vitor is Appia’s Country Manager, Brazil. He has a track record as a portfolio manager and board member. He has held multiple significant positions, including Territory Manager at Shell, as well as Senior Project Planning and Consulting roles at PwC and Petrobras.

Jack Lifton is the company’s Senior Technical Advisor and Consultant. He is an author and lecturer on the market fundamentals of technology metals.

Appia Rare Earths & Uranium Corp. (OTCQX: APAAF), closed Friday's trading session at $0.17505, off by 2.75%, on 200,765 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.075/$0.272.

Recent News

Astrotech Corp. (NASDAQ: ASTC)

The QualityStocks Daily Newsletter would like to spotlight Astrotech Corp. (NASDAQ: ASTC).

Astrotech Corp. (NASDAQ: ASTC) is an instrumentation company that designs, manufactures and commercializes solutions. Its solutions include mass spectrometry, process controls, chemical detectors and medical disease detection.

The company was established in 1984 and, prior to 2009, was known as SPACEHAB Inc., a NASA contractor offering technology originally developed for NASA to monitor air quality on the International Space Station. When the Space Shuttle program ended, the company focused on its satellite processing and mass spectrometer instrumentation units and adopted the Astrotech name.

In 2014, Astrotech sold its satellite subsidiary to focus on its Astrotech Technology Inc. (ATi) mass spectrometry solutions, which offer a number of advantages over competing platforms. Notably, Astrotech’s ATi technology is ruggedized, rapid, simple to use and customizable, with hands-free calibration and tuning.

Between 2016 and 2019, the company secured U.S. patents for its technology and achieved European Union (ECAC) certification for the TRACER 1000™, the world’s first mass-spec Explosives Trace Detector (ETD) used in airports worldwide. Astrotech continues to innovate and add to its suite of products, including AgLAB-1000, a process control system, and the BreathTest 1000, a disease detection solution.

Astrotech is headquartered in Austin, Texas.

Subsidiaries

Astrotech Technologies Inc.

Astrotech Technologies Inc. (ATi) owns and licenses the platform mass spectrometry technology originally developed by 1st Detect. This technology is designed to be less expensive, smaller and easier to use than traditional mass spectrometers.

Unlike other technologies, ATi works under high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The company’s intellectual property includes 18 granted patents, along with extensive trade secrets.

ATi exclusively licenses the Astrotech Mass Spectrometer Technology to the three wholly owned subsidiaries of Astrotech.

1st Detect Corp.

1st Detect Corp. developed the TRACER 1000, the world’s first mass spectrometry-based explosives and narcotics trace detector. 1st Detect ETDs were developed for use at airports, cargo facilities and other secured locations and borders worldwide.

1st Detect’s commercial sales of the TRACER 1000 ETD, consumables and recurring maintenance services brought in $750,000 in total revenue during the fiscal year ended June 30, 2023. The Astrotech subsidiary recently secured two orders for a total of 24 Tracer 1000 units from two Romanian security and telecommunications companies, to be delivered during calendar 2023.

AgLAB Inc.

AgLAB Inc. is developing a series of mass spectrometers for use in the hemp and cannabis market, with an initial focus on optimizing yields in the distillation processes.

AgLAB, which uses the company’s proprietary AgLAB 1000-D2™ mass spectrometer, has been proven to improve distillation oil yields and bottom-line profits for hemp and cannabis producers. During field trials, AgLAB was able to improve ending-weight yields by an average of 24%.

BreathTech Corp.

BreathTech is developing the BreathTest-1000™, a breath analysis tool to screen for volatile organic compound (“VOC”) metabolites found in a person’s breath that could indicate they may have a compromised condition including but not limited to a bacterial or viral infection. The company believes that new tools to aid in the battle against COVID-19 and other diseases remain of the utmost importance to help more quickly identify that an infection may be present.

Market Opportunity

A report by Mordor Intelligence, a research and advisory firm, put the global mass spectrometry market at $6.37 billion in 2023. The market is forecast to grow to $8.63 billion by 2028, achieving a CAGR of 6.25% during the forecast period.

One of the major driving factors for the growth of the mass spectrometry market is technological advancements in mass spectrometer devices, the report states. Key market players are continuously working toward advancing their existing products and launching innovative and advanced mass spectrometer devices.

Another major factor that is expected to boost market growth is increasing research and development expenditure by both government and private entities, according to the report. Mass spectrometry devices are also being used in the detection and analysis of COVID-19 and other disease samples, which may have a positive impact on the market.

Management Team

The Astrotech leadership team includes management executives, as well as industry and technology experts. The company continues to actively expand its talent pool to meet evolving demands.

Thomas B. Pickens III is Chairman, CEO and Chief Technology Officer of Astrotech Corp. He also serves as CEO of Astrotech subsidiaries ATi, 1st Detect, AgLAB Inc. and BreathTech Corp. Previously, he was the founder and president of Beta Computer Systems Inc. and T.B. Pickens & Co. He was founder and general partner of Grace Pickens Acquisition Partners L.P and managing partner of Sumpter Partners. He also served as CEO of Catalyst Energy Corporation and United Thermal Corporation and as president of Golden Bear Corp., United Hydro Inc. and Slate Creek Corp. He received a B.A. in Economics, Computer Science and Engineering from Southern Methodist University.

Jaime Hinojosa, CPA, is CFO at Astrotech Corp. He joined the company in 2015 and has served as its Corporate Controller since 2019. His previous roles with the company include Director of Finance, from 2017 to 2019, and Assistant Controller, from 2015 to 2017. Prior to joining Astrotech, Mr. Hinojosa worked as an Accounting Manager for O’Reilly Auto Parts and gained public accounting experience as an Audit Manager at Burton McCumber & Cortez LLP.

Astrotech Corp. (NASDAQ: ASTC), closed Friday's trading session at $8.49, up 0.236128%, on 5,036 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $7.00/$15.11.

Recent News

Vision Marine Technologies Inc. (NASDAQ: VMAR)

The QualityStocks Daily Newsletter would like to spotlight Vision Marine Technologies Inc. (NASDAQ: VMAR).

Vision Marine Technologies Inc. (NASDAQ: VMAR) is a global leader and innovator within the performance electric recreational boating industry. The company is engaged in designing and manufacturing electric outboard powertrain systems and related technology. It strives to be a guiding force for change and an ongoing driving factor in fighting the problems associated with waterway pollution by disrupting the traditional boating industry with electric power, in turn directly contributing to zero pollution, zero emission and a noiseless environment.

Vision Marine manufactures hand-crafted, highly durable, low maintenance, environmentally friendly electric recreational powerboats. The company’s business segments include the sale and rental of electric boats, with the majority of its revenue attributable to electric boat sales.

The designs and technology applied to Vision Marine’s boats result in enhanced performance, higher speeds and longer range. Put simply, Vision Marine boats offer a smoother ride than a traditional internal combustion engine motorboat.

The company is headquartered in Montreal.

Products

Vision Marine’s flagship E-Motion™ 180E electric marine powertrain is the first fully electric outboard powertrain combining advanced battery pack, inverter and high efficiency motor with proprietary union assembly between the transmission and motor. Vision Marine’s E-Motion and related technologies in this system utilize extensive control software and are uniquely designed to improve the efficiency of the outboard powertrain. As a result, both range and performance are enhanced.

More than a powerful electric outboard motor, the 180E is a complete powertrain package. The high-tech, marine-specific motor is equipped with multi-sensor captors and independent cooling, providing 180 horsepower.

An onboard charging system allows for quick and easy charging from any shore outlet, whether the vessel is in or out of the water. It implements cutting-edge marine battery packs that are IP67 certified and built to withstand the harshest marine environments. The system is glycol cooled with a controlled heat exchanger, ensuring optimal performance and longevity. A stainless-steel casing protects the battery from corrosion and physical damage over time.

The 180E is built to be integrated with many boat models produced by other marine manufacturers. Since boat manufacturers rarely build their own engines, instead choosing to source them from engine manufacturers, Vision Marine believes the 180E propulsion system can in the future end up powering nearly every recreational boat.

Market Opportunity

According to a report from Future Market Insights, a certified market research organization, the global electric boats market is expected to grow from a value of $5.6 billion in 2023 to $15.1 billion by 2033, achieving a CAGR of 10.4% during the forecast period.

Factors driving growth include rising seaborne commerce activities, a flourishing marine tourism industry and stringent emissions regulations aimed at reducing pollution. In addition, government support for electric speedboat adoption, advances in technological development and research and forecast expansion of needed charging infrastructure are credited as growth drivers.

An emphasis on reducing carbon emissions and encouraging consumer adoption of eco-friendly boats is also likely to drive expansion of the market, the report states.

Management Team

Alexandre Mongeon is Co-Founder and CEO of Vision Marine Technologies. He has served as CEO since 2014. Prior to that, he imported high-performance boats from the United States to Canada for more than 15 years. During much of that time, he also worked as a designer and contractor and managed several new construction projects on the waterfront in and around Montreal. He is a graduate of the School of Construction in Laval, Quebec, with a specialization in electrical systems.

Xavier Montagne is Chief Technical Officer at Vision Marine. Prior to joining the company, he was the CEO of Mac Engineering for six years. While there, he was the electric powerline architect of the Renault Trezor concept car (awarded 2016 Best Concept Car), technical designer of the Zoe E-sport race car driven in Formula-E races from 2016-2019 and senior battery designer for Forsee Power, SAFT, Renault and Peugeot in Europe, to mention a few of the many projects he headed. He received an electronic engineer diploma from IFITEP Paris Polytech in France.

Kulwant Sandher is CFO at Vision Marine. He is a Chartered Professional Accountant with more than 25 years of experience in business and finance. He has served as CFO of multiple public and private companies, including ElectraMeccanica Vehicles Corp., MineSense Technologies Inc., Alba Mineral Ltd., Delta Oil & Gas, Astorius Resources Ltd., Norsemont Mining Inc. and Intigold Mines Ltd. He graduated from Queen Mary College, University of London.

Vision Marine Technologies Inc. (NASDAQ: VMAR), closed Friday's trading session at $1.09, off by 2.6786%, on 73,236 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.01/$5.60.

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Friday's trading session at $0.069, even for the day, on 6,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.000001/$0.098.

Recent News

Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.

Lomecel-B™

Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Friday's trading session at $1.36, off by 2.1583%, on 91,398 volume. The average volume for the last 3 months is 397,903 and the stock's 52-week low/high is $1.15/$4.5793.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Friday's trading session at $0.2966, up 5.9286%, on 2,842,266 volume. The average volume for the last 3 months is 725,732 and the stock's 52-week low/high is $0.25/$1.99.

Recent News

Mountain Top Properties Inc. (OTC: MTPP)

The QualityStocks Daily Newsletter would like to spotlight Mountain Top Properties Inc. (OTC: MTPP).

Mountain Top Properties Inc. (OTC: MTPP) is a diversified real estate holding company that acquires, sells and operates assets through its wholly owned subsidiaries and limited partnerships. The company specializes in property management, property technology (“PropTech”) and real estate redevelopment.

Mountain Top Properties was incorporated in 1990 and is based in Liverpool, New York, with offices in Sag Harbor, New York.

Organization

The company’s flagship subsidiary is Mountain Top Realty Inc., the managing partner of its first real estate fund focused on residential redevelopment in the prestigious and storied Hamptons, New York, beachfront communities.

Mountain Top Properties is also the lead investor in blockchain-enabled industrial and warehouse flex space HQXpress, which services the warehousing, reverse logistics and liquidation markets.

The company is in negotiations for the addition of AI-powered technologies that promise to simplify real estate services, including purchasing and sales.

Mountain Top Capital Fund I LLC

Mountain Top Capital Fund I LLC is a New York limited liability company recently organized by affiliates of Mountain Top Realty, manager of the fund. Through this fund, Mountain Top Realty will leverage the company’s experience, market conditions and industry relationships to capitalize on real estate projects as they arise.

This partnership will be focused on waterfront or water view properties in the Hamptons. The Hamptons market has historically remained strong and continues to set new highs year over year.

The fund has partnered with On Site Builder Construction Co. Inc., which is managed by Joseph Kelley, who, for over 40 years, has continued to build the highest quality architecturally designed custom houses, varying in style from classic to ultra-modern, in the Hamptons. Several houses he has built are showcased in books and magazines and featured across various forms of digital and social media. His assembled team of skilled subcontractors are among the finest skilled craftsmen in their various fields of expertise.

Mr. Kelley has built over 60 custom homes in this market and has the unique distinction of building the most expensive house sold in Sag Harbor in 2014, which sold for $31,750,000; the most expensive house in the Hamptons in 2019, which first sold for $27,500,000 in 2017 and later was renovated and re-traded for $39,250,000; and the most expensive house sold in the Hamptons in 2022, which sold with the neighboring house for $118,500,000. Mr. Kelley’s portfolio of projects is valued at over $400,000,000. Although he has historically worked as a custom home builder, he would like to shift from providing a service to now providing a finished product in this market.

Market Opportunity

Mountain Top Capital Fund I has a target to raise $75 million to acquire, renovate and remarket Hamptons waterfront or water view properties. The fund has secured debt capital commitments for 70% of the acquisition costs and 100% of the construction costs and will use $10 million to leverage strategic waterfront opportunities in and around the Hamptons.

Profits from each project will be distributed upon the sale of the project, which is anticipated every 15 to 18 months, with a target of a minimum return on investment of 20% to 30% per transaction.

The company anticipates the fund’s Hamptons projects will be followed up by several other funds targeting additional high-end markets.

Management Team

Beau Kelley is CEO, President, CFO and Director of Mountain Top Properties.

Mountain Top Properties Inc. (OTC: MTPP), closed Friday's trading session at $0.0799, off by 0.125%, on 1,400 volume. The average volume for the last 3 months is 18,838 and the stock's 52-week low/high is $0.0083/$0.1898.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

370 N. Hayden Rd.
Suite 123-591
Scottsdale, AZ 85251
480-374-1336

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .